Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis

Table 1 Baseline Characteristics of Study Population

Variable	All aNSCLC patients	aNSCLC patients who received a mutation test	aNSCLC patients who did not receive a mutation test	p-values	Mutation-positive aNSCLC patients	aNSCLC patients without a test or with negative test result	p-values
N	1741	458	1283	458 vs. 1283 patients	122	1619	122 vs. 1619 patients
Age at index date
Mean	66 97	66 51	67·13	0.441	66 17	67·03	0·633
(Median \| SD)	(68 \|10.20)	(68 \| 10.41)	(68 \| 10.13)		(69 \| 11.35)	(68 \| 10.11)
Gender
Female, N (%)	520 (29·87)	176 (38·43)	344 (26·81)	< 0.001	56 (45·90)	464 (28·66)	< 0.001
TNM status at index date¹
IIIB² (%)	32·17	31·00	32·58	0·535	26·23	32·61	0·146
IV² (%)	43 71	43 45	43 80	0·896	41·80	43·85	0·660
IIIB and IV² (%)	24·12	25·55	23·62	0·407	31 ·97	23·53	0 ·036
At least 1 all-cause hospitalization in baseline²
% of patients	75.99	71·18	77·71	0·005	67·21	76·65	0·019
Number of chronic drugs^2,3
Mean	4·70	4·43	4·69	0·767	4·87	4·68	0·886
(Median \| SD)	(4 \| 3·91)	(4 \| 4·89)	(4 \| 3·92)		(4 \|4·29)	(4 \|3·88)
Charlson Comorbidity Index (CCI) ²
Mean	9·91	9·71	9·98	0·078	9·66	9·93	0·053
(Median \| SD)	(10 \| 2·75)	(9 \| 2·90)	(10 \| 2)	0·078	(9 \| 2·62)	(10 \| 2·76)	0·053

Legend: Table 1 describes baseline characteristics of observed incident aNSCLC patients as well as those of subgroups based on mutation testing and results of the mutation testing
¹TNM stage IIIB ICD-10 codes: C34.8, C.77.0/.1/.2/.3/.4/.5/.8; TNM stage IV ICD-10 codes: C78.X-C79.X; IIIB and IV: Patients who received which had both diagnoses on the same day or within 30 days
²Based on 12 months baseline period
³Defined as at least 2 different prescriptions per ATC class in baseline period

ISSN: 1471-2407